Skip to main content
Client Work

ADVANZ PHARMA Corp. Limited in its U$76 million acquisition of Correvio Pharma Corp.

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

ADVANZ PHARMA Corp. Limited

On May 27, 2020, ADVANZ PHARMA Corp. Limited ("ADVANZ") announced the completion of its plan of arrangement (the "Arrangement") with specialty pharmaceutical company Correvio Pharma Corp. ("Correvio"). Pursuant to the Arrangement, ADVANZ, through a wholly-owned subsidiary, acquired all of the issued and outstanding common shares of Correvio for US$0.42 in cash consideration per share, valuing Correvio’s equity at approximately US$28 million on a fully diluted basis. The acquisition had a total purchase price of approximately US$76 million, which included the repayment of certain Correvio indebtedness.

Team

    Subscribe

    Receive email updates from our team

    Subscribe